Navidea Biopharma (NAVB) Misses Q4 EPS by 9c

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.12), $0.09 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $50 thousand versus the consensus estimate of $1.8 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Goldman "broadly" raises estimates for LTL and truckload stocks